Cargando…

Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII

BACKGROUND: Tissue factor (TF) is expressed in the adventitia of the vessel wall and on extracellular vesicles (EVs) in body fluids. TF and activated coagulation factor (F) VII(a) together form the so‐called extrinsic tenase complex, which initiates coagulation. AIM: We investigated whether EVs in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yong, Repa, Andreas, Lisman, Ton, Yerlikaya‐Schatten, Guelen, Hau, Chi, Pabinger, Ingrid, Ay, Cihan, Nieuwland, Rienk, Thaler, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	HAEMOSTASIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795922/ https://www.ncbi.nlm.nih.gov/pubmed/35748324 http://dx.doi.org/10.1111/jth.15801

Ejemplares similares

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause
por: Hofer, Stefanie, et al.
Publicado: (2019)

Reproductive health and hemostatic issues in women and girls with congenital factor VII deficiency: A systematic review
por: Abdul‐Kadir, Rezan, et al.
Publicado: (2022)

Global hemostatic status in patients with acute‐on‐chronic liver failure and septics without underlying liver disease
por: Lisman, Ton, et al.
Publicado: (2020)

Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease
por: von Meijenfeldt, Fien A., et al.
Publicado: (2020)

Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis
por: van den Boom, Bente P., et al.
Publicado: (2021)

Coagulation signaling from amniotic fluid to fetal skin
por: Hu, Yong, et al.
Publicado: (2022)

Efficacy of pro‐ and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery
por: Bos, Sarah, et al.
Publicado: (2020)

Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay
por: Wan, Jun, et al.
Publicado: (2020)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
por: Robinson, Mary M., et al.
Publicado: (2021)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Comparative sequence analysis of vitamin K‐dependent coagulation factors
por: Stojanovski, Bosko M., et al.
Publicado: (2022)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Characterization of laboratory coagulation parameters and risk factors for intraventricular hemorrhage in extremely premature neonates
por: Roberts, Jonathan C., et al.
Publicado: (2022)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
por: Branchini, Alessio, et al.
Publicado: (2021)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach
por: Winterling, Karina, et al.
Publicado: (2021)

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
por: Chun, Haarin, et al.
Publicado: (2022)

Differences in thrombin and plasmin generation potential between East African and Western European adults: The role of genetic and non‐genetic factors
por: Temba, Godfrey S., et al.
Publicado: (2022)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
por: Pagliari, Maria Teresa, et al.
Publicado: (2022)

The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms
por: Sacco, Monica, et al.
Publicado: (2022)

Diabetes-independent increase of factor VII-activating protease activation in patients with Gram-negative sepsis (melioidosis)
por: de Jong, H K, et al.
Publicado: (2015)

Thromboelastography does not predict outcome in different etiologies of cirrhosis
por: Hugenholtz, Greg C.G., et al.
Publicado: (2017)

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
por: Mir Seyed Nazari, P., et al.
Publicado: (2018)

A hydrophobic patch (PLVIVG; 1481–1486) in the B‐domain of factor V‐short is crucial for its synergistic TFPIα‐cofactor activity with protein S and for the formation of the FXa‐inhibitory complex comprising FV‐short, TFPIα, and protein S
por: Dahlbäck, Björn, et al.
Publicado: (2022)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors
por: Frentsch, Marco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fc8mo7cli33940rsj6pu1ikdpq